anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
LATISSE® solution was evaluated for its effect on overall eyelash prominence in a multicenter, double-masked, randomized, vehicle-controlled, parallel study including 278 adult patients for four months of treatment. The primary efficacy endpoint in this study was an increase in overall eyelash prominence as measured by at least a 1-grade increase on the 4-point Global Eyelash Assessment (GEA) scale, from baseline to the end of the treatment period (week 16). LATISSE® was more effective than vehicle as measured by the GEA score, with statistically significant differences seen at 8-week, 12-week, and 16-week (primary endpoint) treatment durations. 

In this study, patients were also evaluated for the effect of LATISSE® solution on the length, thickness and darkness of their eyelashes. Improvements from baseline in eyelash growth as measured by digital image analysis assessing eyelash length, fullness/thickness, and darkness were statistically significantly more pronounced in the bimatoprost group at weeks 8, 12, and 16.

* a negative value is representative of eyelash darkening

After the 16-week treatment period, a 4-week post-treatment period followed during which the effects of bimatoprost started to return toward baseline. The effect on eyelash growth is expected to abate following longer term discontinuation.
Control group will have access to the same exercise video and guided for the first session. They will be asked to do the exercises at home, exact the same duration and frequency of the experimental group but without supervision, for 8 weeks.
One of the main causes of implant failure and revision surgery in total hip replacement (THR) is aseptic loosening often caused by the accumulation of wear debris arising between the contact surfaces of the acetabular cup and femoral head during activities of daily living (ADL's). However, limited information is available regarding the contact force pathways between these two surfaces during specific ADL's. In this study, through musculoskeletal modelling, we aimed to estimate the orientation of the hip contact force pathway on the acetabular cup. One hundred and thirty-two THR patients underwent motion capture analysis whilst undertaking locomotor and non-locomotor ADL's. Musculoskeletal simulations were performed to calculate contact force pathways using inverse dynamics analysis. We then qualitatively compared differences in the contact force pathways between patients and between ADL's. Walking resulted in a typical figure-of-eight pattern, with the peak contact forces occurring in the superior-anterior area of the cup. The non-locomotive activities such as stand up, sit down and squat had a more linear shape, spanning across the superior-posterior quarter of the cup. Our results showed a large inter-patient variability in the shape and location of the contact force pathway. There is a distinct difference in the location and shape of the pathway between locomotor and non-locomotor activities and this could result in different wear accumulations. These results could enhance our understanding why revision rates vary across the population and could inform the development of personalised implant design.
Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25°C. of at least about 10 cps or about 100 cps at a shear rate of 0. I/second. In a preferred embodiment, the viscosity at 25°C. is in the range of from about 80,000 cps to about 300,000 cps.
Alternate-day intermittent fasting. Consumption of 25% of daily energy requirements on scheduled fasting days involving energy restriction for 2 non-consecutive days of the week and ad libitum feeding on the other 5 days of the week. Period: 8 weeks.
Participants received 20 mg apremilast orally twice a day (BID) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 20 mg apremilast BID for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 20 mg BID thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.
The present invention relates to a system provides assisted living messages with varying levels of detail to a person, according to proximity gradients. In one embodiment, the system involves location data. The location data associates first and second notification devices with respective first and second locations at a dwelling. A remote configuration module may enable a caregiver at a location other than the dwelling to specify multiple messages to be presented to the person at the dwelling, to assign first and second messages among the multiple messages to the first location, and to associate the first and second messages with first and second proximities, respectively, for the first location. The first notification device may automatically present the first message in response to detecting the person within the first proximity, and the second message in response to detecting the person within the second proximity. Other embodiments are described and claimed.
Each year, nearly 19 million people die of cardiovascular disease with coronary heart disease and myocardial infarction (MI) as the leading cause of the progression of heart failure. Due to the high risk associated with surgical procedures, a variety of minimally invasive therapeutics aimed at tissue repair and regeneration are being developed. While biomaterials delivered via intramyocardial injection have shown promise, there are challenges associated with delivery in acute MI. In contrast, intravascularly injectable biomaterials are a desirable category of therapeutics due to their ability to be delivered immediately post-MI via less invasive methods. In addition to passive diffusion into the infarct, these biomaterials can be designed to target the molecular and cellular characteristics seen in MI pathophysiology, such as cells and proteins present in the ischemic myocardium, to reduce off-target localization. These injectable materials can also be stimuli-responsive through enzymes or chemical imbalances. This review outlines the natural and synthetic biomaterial designs that allow for retention and accumulation within the infarct via intravascular delivery, including intracoronary infusion and intravenous injection.
Long non-coding RNAs (lncRNAs) have emerged as pivotal regulators in numerous biological processes, including macrophage-mediated inflammatory responses, which play a critical role in the progress of diverse diseases. This study focuses on the regulatory function of lncRNA brain and reproductive organ-expressed protein (BRE) antisense RNA 1 (BRE-AS1) in modulating the inflammatory activation of monocytes/macrophages. Employing the THP-1 cell line as a model, we demonstrate that lipopolysaccharide (LPS) treatment significantly upregulates BRE-AS1 expression. Notably, specific knockdown of BRE-AS1 via siRNA transfection enhances LPS-induced expression of interleukin (IL)-6 and IL-1β, while not affecting tumor necrosis factor (TNF)-α levels. This selective augmentation of pro-inflammatory cytokine production coincides with increased phosphorylation of Janus kinase (JAK)2 and signal transducer and activator of transcription (STAT)3. Furthermore, BRE-AS1 suppression results in the downregulation of suppressor of cytokine signaling (SOCS)3, an established inhibitor of the JAK2/STAT3 pathway. Bioinformatics analysis identified binding sites for miR-30b-5p on both BRE-AS1 and SOCS3 mRNA. Intervention with a miR-30b-5p inhibitor and a synthetic RNA fragment that represents the miR-30b-5p binding site on BRE-AS1 attenuates the pro-inflammatory effects of BRE-AS1 knockdown. Conversely, a miR-30b-5p mimic replicated the BRE-AS1 attenuation outcomes. Our findings elucidate the role of lncRNA BRE-AS1 in modulating inflammatory activation in THP-1 cells via the miR-30b-5p/SOCS3/JAK2/STAT3 signaling pathway, proposing that manipulation of macrophage BRE-AS1 activity may offer a novel therapeutic avenue in diseases characterized by macrophage-driven pathogenesis.
This document discloses a colorless composition comprising metal particles (e.g., silver nanoparticles) and water. Said particles comprise an interior of elemental metal (e.g., silver) and an exterior of metal oxide (e.g., one or more silver oxide(s)). And the metal nanoparticles are present in the water at a level of about 5-40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described. Such compositions can be incorporated into a hydro-gel with essentially no loss of antimicrobial properties. In this document are also disclosed various metal-containing compositions with unexpected biological efficacy are also disclosed.
Intermittent complete androgen suppression therapy starting at randomization with interruption of treatment given in the induction period until PSA levels reach \>=10 ng/mL or other signs of progression appear. Upon treatment resumption, leuproreline 3.75 mg SR, injection, subcutaneously once every 28 days and flutamide 250 mg, tablet, orally thrice daily, until PSA levels are \<normal (that is, \<4 ng/mL) and no signs of disease progression appear. The intermittent therapy will be continued similarly until the study end or the appearance of signs of disease progression under treatment.
The quick-release preparation for targeted therapy of hyperlipidemic acute pancreatitis consists of a basic solution and drug-loaded microbubbles. The basic solution comprises sodium alginate and trehalose, wherein the mass ratio of the sodium alginate to the trehalose is 1:10. The drug-loaded microbubbles consist of nitric oxide microbubbles that carry insulin. The nitric oxide microbubbles are vesicles formed by wrapping nitric oxide gas with hydrogenated soybean phospholipid and heparin-poloxamer as membrane material, and the mass ratio of the hydrogenated soybean phospholipid to the heparin-poloxamer is 1:2. Insulin is adhered to the surface of nitric oxide microbubbles with the same molar mass as heparin-poloxamer. The particle diameter of the drug-carrying microbubbles is 2-5 μm, and the concentration in the quick-release preparation is 1×10  6  ～5×10  6  And each mL. The quick-release preparation provided by the invention realizes accurate positioning and targeted delivery of the pancreas part through an ultrasonic mediated technology after intravenous injection, and is used for treating the acute pancreatitis of hyperlipidemia.
The process comprises reaction of a halogenated deriv.. of formula (II) where X is a Cl or Br atom with a sec. amine (III) where R is (1-6)C lower alkyl gp. The reaction is carried out in a solvent such as toluene at between 60 and 140 deg.C and in the presence of a carbonate or bicarbonate. The inorganic salts are finally sepd. by pptn. in water or filtration, the prod. of general formula (I) being isolated by vacuum distn.
PURPOSE: Currently, the most used peptide receptor radionuclide therapy (PRRT) regimen for neuroendocrine tumors comprises 4 treatment cycles, and there is not enough large-scale data to support the safety of more individualized extended PRRT. This study aims to evaluate the therapeutic effectiveness and potential nephrotoxicity related to PRRT using more than four treatment cycles.
METHODS: In this retrospective analysis, we included patients who had received at least four PRRT cycles and had available follow-up data. We analyzed renal function indicators before and after multiple treatments, comparing nephrotoxicity in patients receiving four cycles ("standard") with those receiving more than four ("extended treatment"). Nephrotoxicity was assessed via creatinine levels and CTCAE creatinine grades. Treatment effectiveness was gauged using Kaplan-Meier survival analysis, focusing on overall survival and disease-specific survival (DSS). Statistical analyses were performed using SPSS version 26 (IBM), R 4.2.3, and GraphPad Prism 9.0.0. Statistical significance was defined as a P-value of less than 0.05.
RESULTS: Our study cohort consisted of 281 patients in the standard group and 356 in the extended treatment group. No significant differences in baseline characteristics or renal function were noted between the two groups pre-treatment. Mean post-treatment creatinine levels did not significantly differ between the standard (89.30 ± 51.19 μmol/L) and extended treatment groups (93.20 ± 55.98 μmol/L; P = 0.364). Similarly, there was no statistical significance between the CTCAE creatinine grades of the two groups (P = 0.448). Adverse renal events were observed in 0.4% of patients in the standard group and 1.1% in the extended treatment group. After a median follow-up time of 88.3 months, we found that median overall survival was significantly higher in the extended treatment group (72.8 months) compared to the standard treatment group (52.8 months). A Cox regression analysis further supported these findings, indicating a better prognosis for the extended treatment group in terms of overall survival (HR: 0.580, P < 0.001) and DSS (HR: 0.599, P < 0.001).
CONCLUSION: Our findings suggest that extending PRRT treatment beyond the standard four cycles may be a safe and effective therapeutic strategy for NET patients. This approach could be particularly beneficial for patients experiencing disease recurrence or progression following standard treatment.
FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on week 0, week 4, week 8, week 12, week 24, week 36, week 48, week 60, week 72, week 84.
PURPOSE:To obtain titled product free from any degradation even during a long storage period, providing excellent frothing performance when charged in water, to effect complete dissolution, by incorporating boron oxide in a granular formulation comprising a hydrogen peroxide adduct and others followed by press molding. CONSTITUTION:The objective product can be obtained by first incorporating (A) 100pts.wt. of a granular formulation comprising (i) 100pts.wt. of a hydrogen peroxide adduct, and (ii) 4-500pts.wt. of a chlorinated isocyanuric acid or peroxysulfuric acid (hydrogen) salt, or (iii) 100pts.wt. of an alkali metal (bi)carbonate and (iv) 10-100pts.wt. of a solid (in)organic acid with (B) 0.1-3pts.wt. of boron oxide, followed by carrying out a press molding under a pressure, normally, of 50-600kg/cm<2>. USE:Cleaning agents for medical, industrial, and domestic use; for example, a cleaning agent for articicial teeth.
The present invention relates to 2-mercapto-ethylamine cyclized hypocrellin and preparation method and use thereof. Hypocrellin and cysteamine or cysteine having the molar ratio of 1: 2 to 1: 20 are mixed with a polarity organic solvent-a buffering solution and react for 15 to 40 minutes, and then the reactant is neutralized to neutrality by acid. Derivatives I and II of the aminated hypocrellin are extracted by chloroform, and a chloroform layer is obtained after the cysteamine reacts with the hypocrellin. For derivatives III and IV of the aminated hypocrellin, a water layer is obtained after back extraction by chloroform after the cysteine reacts with the hypocrellin. The total yield of the compounds I and II reaches 93%, and the total yield of the compounds III and IV reaches 70%. The absorption of the compounds is greatly enhanced in a phototherapy window, and the compounds can be used for treating tumour, resisting AIDS and purifying blood.
PURPOSE: A cosmetic composition containing a porcine placenta-derived adult stem cell culture liquid or a protein thereof is provided to enhance the anti-wrinkle and anti-aging properties of cosmetics. CONSTITUTION: A functional cosmetic composition contains a porcine placenta-derived adult stem cell culture liquid as an active ingredient. The functional cosmetic composition additionally contains a protein extracted from the adult stem cells. peptides, or amino acids of the protein. The cosmetic composition is used in the form of a lotion, emulsion, cream, gel, essence, or pack. A method for manufacturing the culture liquid comprises: a step of isolating amnion from porcine placenta; a step of collecting adult stem cells from the amnion; and a step of culturing the adult stem cells in a medium containing bFGF.
BACKGROUND: Herpes zoster (HZ) is one of the most common skin diseases caused by viruses. Facial HZ develops when the varicella-zoster virus affects the trigeminal nerve, and alveolar osteonecrosis is a rare complication. However, the exact pathogenesis of postherpetic alveolar osteonecrosis remains unclear.
CASE DESCRIPTION: We encountered a patient who presented to the dermatology clinic with facial HZ and tooth exfoliation in the upper right jaw, and panoramic radiography revealed decreased bone density and poor alveolar socket healing in his right maxilla. Biopsy of the alveolar process revealed fragments of nonvital lamellar bone, which were devoid of osteoblasts and osteocytes and were surrounded by numerous neutrophils and bacterial aggregates. Thus, the diagnosis of alveolar osteonecrosis following facial HZ was confirmed. He then underwent resection of the osteonecrotic tissue. The pathological findings of postoperative tissue were similar to those of previous biopsies. Varicella-zoster virus and multiple types of bacteria were detected through next-generation sequencing, and the species of bacteria were consistent with the results of bacterial culture. Antibiotics and valaciclovir were administered during the perioperative period. The patient showed good recovery at the 9-month follow-up.
CONCLUSIONS: The coexistence of bacterial and viral infection may play an important role in the pathogenesis of alveolar osteonecrosis following HZ. To our knowledge, we are the first to directly explore microbial pathogens in a case of postherpetic alveolar osteonecrosis through next-generation sequencing and bacterial culture. We recommend that oral examinations be carefully conducted for patients who are diagnosed with facial HZ, even if their facial rashes have faded away. We suggest that a prolonged and full-dose antiviral therapy course may be beneficial for the treatment of facial HZ with intraoral lesions. The implementation of dental preventive measures should be considered for patients with facial HZ. The application of antibiotics and excision of necrotic bone may reduce the abundance of bacteria in lesions and improve wound healing.
PROBLEM TO BE SOLVED: To obtain a antitumor agent which possesses inhibitory effect on proliferation of tumor cells, anticancer activity, cancer metastasis inhibitory effect and angiogenesis inhibitory activity and is useful for treating malignant tumor by formulating specific peptides as active ingredients. SOLUTION: This antitumor agent is obtained by formulating a peptide consisting of 5 to 20 amino acids containing the amino acid sequence of the fomaula, its peptide derivative, pharmacologically permissible salts (e.g. acid- addition salts, metal complexes, carboxylate salts, etc.), of the peptide and the derivative or these mixtures as an active ingredient preferably in an amount of at least 5 mg per 1 g of the final composition. As the other component, fillers, bulking agents and binders can be illustrated. The objective antitumor agent can be administrated by e.g. intravenous injection, subcutaneous injection and oral administration to humans or animals. As the dosage form, tablet, pill, powder, liquid and injection are illustrated. In the case of subcutaneous administration, the effective dosage is 1 mg/body weight 1 kg/day.
Propolis is an immunomodulatory, antioxidant, flavonoid-rich resinous product of honeybees. Propolis was reported as less cytotoxic and more effective against resistant microorganisms than calcium hydroxide as well as biocompatible to the periradicular tissues than existing intracanal medicaments. The aim of this single-blinded randomized clinical trial was to evaluate the effect of propolis versus calcium hydroxide, intracanal medicaments, on post-operative pain in patients with necrotic single canal teeth. Methods: Forty-six participants with an age range of 20-40 years old, diagnosed as having necrotic pulp in their single-rooted, single canal teeth were included in this study, with 23 participants in each group. Treatment was done in two visits and intracanal medicament was applied for one week in between. Participants were instructed to rate their pain score by a numerical rating scale after 24, 48, 72 hours and at 7 days.
PURPOSE: To prepare a formulation, comprising a gel matrix, a protein entrapped into the gel matrix and an ingredient capable of binding to the entrapped protein such as a drug or an antibiotic substance and capable of hydrolyzing the protein with a proteolytic enzyme and releasing the ingredient from the protein to a desired site. CONSTITUTION: This controlled-release formulation comprises a gel matrix (preferably polysaccharides capable of gelling such as pectin, a pectate, carrageenan or guar gum and further containing Mg, Zn, Al, etc.), a protein entrapped into the gel matrix (especially casein, blood serum albumin, etc.) and an ingredient capable of binding to the entrapped protein (a drug, an antibiotic substance, a hormone, a hormone analog, a chemotherapeutic agent, etc., are especially preferred). The formulation is designed to hydrolyze the protein with a proteolytic enzyme (trypsin, etc., are especially preferred) and release the ingredient from the protein into conditions containing an enzyme. The gel matrix is capable of assuming a shape such as a membrane, a fiber or a pipe.
The invention relates to the field of Chinese herbal medicine health-care food, in particular to sealwort medlar tea and a preparation method thereof, wherein the sealwort medlar tea comprises the following raw materials in parts by weight: 28-55 parts of rhizoma polygonati, 15-35 parts of medlar, 8-23 parts of tuckahoe and 3-18 parts of liquorice. The preparation method comprises pulverizing the raw materials; drying the crushed raw materials; and then bagging, boxing and storing. The polygonatum sibiricum and medlar tea is prepared from multiple Chinese herbal medicines by reasonable compatibility, the raw materials are medicinal and edible Chinese herbal medicines, the medicinal properties of the raw materials are mild and safe, and no side effect is caused. Meanwhile, the tea has the color, the aroma and the taste of the tea and good palatability. The compatibility of the invention mainly takes the middle-jiao and Qi tonifying, Yin and Yang tonifying medicine as the main medicine and takes the diuresis inducing and dampness removing medicine as the auxiliary medicine. Has the effects of strengthening body resistance, consolidating constitution, invigorating spleen and kidney, promoting qi circulation, eliminating pathogenic factors, removing blood stasis, improving renal function, and improving frequent micturition, urgent micturition, incomplete micturition, dark urine, odynuria, dysuria, and nocturia. The invention packs the crushed raw materials in bags, is convenient for brewing and drinking, and is easy for patients to insist on long-term conditioning.